Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy, accounting for approximately 80% of leukemia in the pediatric group, and its etiology is unknown. This neoplasia is characterized by male predominance, high-risk features and poor outcome, mainly in recurrence patients and adul...
Hemminki & Kyyrönen found a positive association of leukemia incidence with maternal, but not paternal age. Another study46, of non-Hodgkin lymphoma incidence, found the opposite result; a positive association with paternal but not maternal age. Our analysis of lymphatic cancer mortality combined...
Hemminki & Kyyrönen found a positive association of leukemia incidence with maternal, but not paternal age. Another study46, of non-Hodgkin lymphoma incidence, found the opposite result; a positive association with paternal but not maternal age. Our analysis of lymphatic cancer mortality combined...
Case presenation of a rare clinical manifestation of a relapse of acute lymphoblastic leukemia in a young woman manifested by growing uterus mimicking a myomatous uterus...Tinkering with the Glucose Homeostasis - Oral Therapies for Type 2 Diabetes Mellitus Henry J T Sai Journal of Diabetic Compli...
High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults J Clin Oncol, 35 (4) (2017), pp. 394-401 View in ScopusGoogle Scholar 22 S Chiaretti, A Vitale, G Cazzaniga, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leu...
A pivotal phase 2 trial of WU-CART-007, an anti-CD7 CAR T-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma treatment, will begin in 2025. Microscopic image of CAR T cells - Generated with...
Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). EP: 1.Overview of Characteristics Unique to Ph+ ALL ...
CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target. Cell Mol Life Sci 2015; 72:1715-23Aparecida, de Lourdes PerimMarla Karine, AmaranteRoberta Losi, GuembarovskiCarlos Eduardo Coral, de OliveiraMaria Angelica E...
Leukemia 16 (4): 508–519. Article CAS Google Scholar Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ (2004) Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64 (18): 6461–6468. Article CAS Google Scholar Wu QJ,...
You or Your Caregiver to Call the Office - Integrative Medicine, Quality of Life & Concerns About Life Expectancy - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Adherence & Discussion of OpenNotes - Questions for Our Panel of ...